Tamarixetin Exhibits Anti-inflammatory Activity and Prevents Bacterial Sepsis by Increasing IL-10 Production,Journal of Natural Products

当前位置： X-MOL 学术 › J. Nat. Prod. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tamarixetin Exhibits Anti-inflammatory Activity and Prevents Bacterial Sepsis by Increasing IL-10 Production
Journal of Natural Products ( IF 3.3 ) Pub Date : 2018-05-31 00:00:00 , DOI: 10.1021/acs.jnatprod.8b00155
Hee Jo Park ₁ , Seung Jun Lee ₁ , Joon Cho ₂ , Amal Gharbi ₁ , Hee Dong Han ₁ , Tae Heung Kang ₁ , Yangmee Kim ₃ , Yeongjoon Lee ₃ , Won Sun Park ₄ , In Duk Jung ₁ , Yeong-Min Park ₁

Affiliation

Sepsis is a systemic inflammatory response to pathogenic infection that currently has no specific pharmaceutical interventions. Instead, antibiotics administration is considered the best available option, despite increasing drug resistance. Alternative strategies are therefore urgently required to prevent sepsis and strengthen the host immune system. One such option is tamarixetin (4′-O-methylquercetin), a naturally occurring flavonoid derivative of quercetin that protects against inflammation. The purpose of this study was to determine whether the anti-inflammatory effects of tamarixetin protect against the specific inflammatory conditions induced in lipopolysaccharide (LPS) or Escherichia coli K1 models of sepsis. Our study showed that tamarixetin reduced the secretion of various inflammatory cytokines by dendritic cells after activation with LPS. It also promoted the secretion of the anti-inflammatory cytokine interleukin (IL)-10 and specifically increased the population of IL-10-secreting immune cells in LPS-activated splenocytes. Tamarixetin showed general anti-inflammatory effects in mouse models of bacterial sepsis and decreased bacteria abundance and endotoxin levels. We therefore conclude that tamarixetin has superior anti-inflammatory properties than quercetin during bacterial sepsis. This effect is associated with an increased population of IL-10-secreting immune cells and suggests that tamarixetin could serve as a specific pharmaceutical option to prevent bacterial sepsis.

中文翻译：

他马西汀显示出抗炎活性，并通过增加IL-10的产生来预防细菌性败血症

脓毒症是对病原体感染的全身性炎症反应，目前尚无特异性药物干预措施。取而代之的是，尽管耐药性增加，但仍认为抗生素管理是最佳的选择。因此，迫切需要替代策略来预防败血症和加强宿主免疫系统。一种这样的选择是他马西汀（4'- O-甲基槲皮素），它是槲皮素的天然存在的类黄酮衍生物，具有抗炎症作用。这项研究的目的是确定他玛西汀的抗炎作用是否可抵抗脂多糖（LPS）或大肠杆菌诱导的特定炎性疾病败血症的K1模型。我们的研究表明，他莫西汀经LPS激活后，可减少树突状细胞分泌各种炎性细胞因子。它还促进了抗炎细胞因子白介素（IL）-10的分泌，并特别增加了LPS激活的脾细胞中分泌IL-10的免疫细胞的数量。他马西汀在细菌性败血症的小鼠模型中显示出一般的抗炎作用，并降低了细菌的丰度和内毒素水平。因此，我们得出结论，在细菌性脓毒症期间，他马西汀比槲皮素具有更好的抗炎特性。这种作用与分泌IL-10的免疫细胞数量增加有关，表明他马西汀可以作为预防细菌性败血症的特定药物选择。

更新日期：2018-05-31

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南